Jacobs Journal of Allergy and Immunology
Volume 2 Issue 2
MicroRNAs are Potential Biomarkers and Therapeutic Targets of Atopic Dermatitis
Won Suck Yoon, Young Yoo, Tae Ho Lee, Sung Ha Park, Byeong Mo Kim*
microRNAs (miRNAs) are a class of small, non-coding RNAs that regulate the expression of a diverse array of genes and pathways, with important roles in disease pathogenesis. Many of these miRNAs are currently under investigation as biomarkers or therapeutic options in a range of diseases. Here, we discuss the role of miRNAs in atopic dermatitis, a relapsing chronic pruritic inflammatory skin disease of unknown etiology, as they have been strongly implicated in the pathogenesis of skin inflammation.
Vitamin D3 plus Lactobacillus reuteri DSM 17938 as Adjuvant for Allergen Immunotherapy: A Preliminary Experience
Giorgio Ciprandi*, Attilio Varricchio
Allergic patients have paradigmatically an allergen-specific functional defect of T regulatory cells (Tregs) and a Th2-polarized immune response. This characteristic immunological pattern promotes IgE production and mucosal inflammation, which is closely dependent on the causal allergen exposure. Indeed, after inhaling sensitizing allergen, allergic subjects develop inflammation and present symptoms.
The Discovery of Low-Abundance Allergens by Proteomics Analysis Involving Combinatorial Peptide Ligand Libraries
Egisto Boschetti*, Elisa Fasoli and Pier Giorgio Righetti
Allergic reactions are biological processes of defense against foreign products that are considered external dangerous agents of various origins. The latter, allergens, modify the expression of immunoglobulins E and G and produce serious reactions that can be life threatening. The increased occurrence of allergic reactions stimulates the investigations around the discovery of novel protein agents, which has been made possible by novel technologies developed for proteomics research where from numerous novel allergens, particularly those of low abundance, have been detected.
Exhaled nitric oxide (eNO) in the evaluation and treatment of mild intermittent asthma
Andrew Ayars, MD*, Stephen Tilles, MD, Leonard Altman, MD
Asthma is traditionally diagnosed and managed based on clinical history and pulmonary function testing and in recent years there has been an effort to develop biomarkers to aid in the diagnosis and management. Exhaled nitric oxide (eNO) is a biomarker that is gaining popularity for use in clinical practice. In this study we evaluated the utility of this biomarker in the diagnosis and management of asthma by comparing eNO with clinical history, asthma control test (ACT), and FEV1% in 10 subjects with mild intermittent asthma.